Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Y F L De Vos

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Frontiers in Neurology|December 6, 2021
Added Value of Cognition in the Prediction of Survival in Low and High Grade GliomaEmma van Kessel, Ewoud Schuit, Irene M C Huenges Wajer, et al.
BMC Health Services Research|October 1, 2025
Timely integration of palliative care into oncology in hospitals in the Netherlands: a feasibility studyCarly S Heipon, Linda Brom, Wendy M van der Deure, et al.
Clinical Nuclear Medicine|May 27, 2025
Imaging Proliferation of Stage IV Cutaneous Melanoma With 18 F-FLT PET/CT : A Potential Noninvasive Tool for Predicting Treatment Resistance to Targeted Therapy?Bernies van der Hiel, Wouter V Vogel, Alfons J M van den Eertwegh, et al.
Neuro-Oncology Practice|July 20, 2022
Complications, compliance, and undertreatment do not explain the relationship between cognition and survival in diffuse glioma patientsEmma van Kessel, Eva A Krijnen, Suzanne IJpelaar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2005
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancerRonald Hoekstra, Filip Y F L de Vos, Ferry A L M Eskens, et al.
Neuro-Oncology Practice|July 15, 2026
Functional outcome after repeat surgery of tumor progression or treatment-associated changes in high-grade glioma: Clinical and radiological predictorsAnouk M de Jong, Maud E Kortman, Maarten W Kreek, et al.
Targeted Oncology|February 12, 2019
Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520Remy B Verheijen, Diane A J van der Biessen, Sebastien J Hotte, et al.
Clinical Nuclear Medicine|May 20, 2024
Baseline and on Treatment Biodistribution Variability of 18 F-FLT Uptake in Patients With Advanced Melanoma: Brief CommunicationBernies van der Hiel, Else A Aalbersberg, Alfons J M van den Eertwegh, et al.
BMC Cancer|September 1, 2022
Characteristics of patients with advanced cancer preferring not to know prognosis: a multicenter survey studyNaomi C A van der Velden, Hanneke W M van Laarhoven, Sjaak A Burgers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2019
Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based ChemotherapyPadmanee Sharma, Joohyuk Sohn, Sang Joon Shin, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Frontiers in Neurology|December 6, 2021
Added Value of Cognition in the Prediction of Survival in Low and High Grade GliomaEmma van Kessel, Ewoud Schuit, Irene M C Huenges Wajer, et al.
BMC Health Services Research|October 1, 2025
Timely integration of palliative care into oncology in hospitals in the Netherlands: a feasibility studyCarly S Heipon, Linda Brom, Wendy M van der Deure, et al.
Clinical Nuclear Medicine|May 27, 2025
Imaging Proliferation of Stage IV Cutaneous Melanoma With 18 F-FLT PET/CT : A Potential Noninvasive Tool for Predicting Treatment Resistance to Targeted Therapy?Bernies van der Hiel, Wouter V Vogel, Alfons J M van den Eertwegh, et al.
Neuro-Oncology Practice|July 20, 2022
Complications, compliance, and undertreatment do not explain the relationship between cognition and survival in diffuse glioma patientsEmma van Kessel, Eva A Krijnen, Suzanne IJpelaar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2005
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancerRonald Hoekstra, Filip Y F L de Vos, Ferry A L M Eskens, et al.
Neuro-Oncology Practice|July 15, 2026
Functional outcome after repeat surgery of tumor progression or treatment-associated changes in high-grade glioma: Clinical and radiological predictorsAnouk M de Jong, Maud E Kortman, Maarten W Kreek, et al.
Targeted Oncology|February 12, 2019
Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520Remy B Verheijen, Diane A J van der Biessen, Sebastien J Hotte, et al.
Clinical Nuclear Medicine|May 20, 2024
Baseline and on Treatment Biodistribution Variability of 18 F-FLT Uptake in Patients With Advanced Melanoma: Brief CommunicationBernies van der Hiel, Else A Aalbersberg, Alfons J M van den Eertwegh, et al.
BMC Cancer|September 1, 2022
Characteristics of patients with advanced cancer preferring not to know prognosis: a multicenter survey studyNaomi C A van der Velden, Hanneke W M van Laarhoven, Sjaak A Burgers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2019
Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based ChemotherapyPadmanee Sharma, Joohyuk Sohn, Sang Joon Shin, et al.
Pageof 5